We are pleased to announce that the development of our CDMO's conceptual, basic and executive projects has begun!
Last month we closed a partnership with PQE Group to develop the Conceptual, Basic and Executive projects of our CDMO.
PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities deliverable throughout the entire product quality life cycle. With offices located worldwide and a full-ranged broad service portfolio, extensive experience, effective project management, PQE’s solutions are the winning combination for global corporations, as well as small and medium sized companies.
With a total available area of more than 5,000 m2, Biotimize will build its new R&D Center (GLP) and CDMO (GMP) in a space of approximately 3,000 m2, in Piracicaba/SP. The objective of the CDMO (GMP) is to generate cell banks (WCB and MCB), produce clinical materials (phase I-III) and commercial batches focused on the mammalian cell expression platform. Furthermore, the R&D Center will be used for cell line development, process development, formulation development, development of analytical methods and production of pre-clinical materials from different expression platforms.
In the outlined roadmap, the executive project will be completed in June 2024, and as a result, the construction of the R&D Center and CDMO will begin. The expectation is that the new R&D Center will be inaugurating in the first quarter of 2025, and the CDMO, in the first quarter of 2026.
Want to know more about our expansion project? Access our website!